InterCure (IL:INCR)
TASE:INCR
Want to see IL:INCR full AI Analyst Report?
INCR Stock Chart & Stats
514.20
>-0.01(-0.10%)
At close: 4:00 PM EST
514.20
>-0.01(-0.10%)
Day’s Range― - ―
52-Week Range225.30 - 605.00
Previous CloseN/A
Volume249.40K
Average Volume (3M)91.19K
Market Cap
₪196.31M
Enterprise Value332.85M
Total Cash (Recent Filing)₪51.58M
Total Debt (Recent Filing)₪179.34M
Price to Earnings (P/E)―
Beta0.88
Next Earnings
Aug 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.62
Shares Outstanding54,681,335
10 Day Avg. Volume173,192
30 Day Avg. Volume91,185
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)0.46
Price to Sales (P/S)0.68
P/FCF Ratio13.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improved Cash GenerationMaterial positive operating and free cash flow in 2025 strengthens liquidity and reduces near-term financing needs. Durable cash generation supports reinvestment in cultivation, retail and product development, enabling organic growth and operational resilience if management sustains discipline.
Revenue RecoveryA return to revenue growth after multiple down years signals demand recovery and improved commercial execution across wholesale and retail channels. Sustained top-line momentum supports scale economics, potential margin normalization, and long-term profitability if trends continue beyond a single-year rebound.
Manageable LeverageModerate debt-to-equity provides financial flexibility to fund operations and selective investments without excessive solvency risk. The improvement versus 2024 indicates de-leveraging progress, preserving capacity for strategic spending or absorbing temporary revenue shocks while avoiding overreliance on external capital.
Bears Say
Persistent Net LossesMulti-year net losses and a negative net margin indicate the core business has not yet delivered sustainable profitability. Continued operating losses can erode equity, limit retained earnings for growth, and force reliance on external funding, raising execution and dilution risk over the medium term.
Multi-year Negative ROEThree consecutive years of negative ROE show the company is not generating acceptable returns on shareholder capital. This structural shortfall undermines investor confidence, may constrain access to cheaper capital, and increases pressure to either materially improve margins or pursue equity raises.
Cash Flow Volatility RiskSharp swings from large outflows in 2023–24 to positive cash flow in 2025 highlight volatility in working capital and operations. Such volatility raises refinancing and planning risk, making sustained investment in retail expansion or product development more uncertain without predictable free cash flow.
Intercure News
INCR FAQ
What was InterCure’s price range in the past 12 months?
InterCure lowest stock price was 225.30 and its highest was 605.00 in the past 12 months.
What is InterCure’s market cap?
InterCure’s market cap is ₪196.31M.
When is InterCure’s upcoming earnings report date?
InterCure’s upcoming earnings report date is Aug 17, 2026 which is in 77 days.
How were InterCure’s earnings last quarter?
InterCure released its earnings results on Feb 19, 2026. The company reported -62.8 earnings per share for the quarter, missing the consensus estimate of N/A by -62.8.
Is InterCure overvalued?
According to Wall Street analysts InterCure’s price is currently Overvalued.
Does InterCure pay dividends?
InterCure does not currently pay dividends.
What is InterCure’s EPS estimate?
InterCure’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does InterCure have?
InterCure has 54,681,335 shares outstanding.
What happened to InterCure’s price movement after its last earnings report?
InterCure reported an EPS of -62.8 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.696%.
Which hedge fund is a major shareholder of InterCure?
Currently, no hedge funds are holding shares in IL:INCR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
InterCure
InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Israel and internationally. It offers dried cannabis inflorescences and cannabis extract mixed with oil. The company also invests in biomed sector. InterCure Ltd. was incorporated in 1994 and is headquartered in Herzliya, Israel.